

## Contents

**Preface** XIII

**Acknowledgments** XV

**Limit of Liability/Disclaimer of Warranty** XVII

**Executive Summary** 1

<b>1</b>	<b>Introduction</b>	7
1.1	Development of the Private Equity and Venture Capital Market	7
1.1.1	Definition	7
1.1.2	Historical Background	10
1.1.3	The Challenges to Private Equity in Europe	12
1.1.4	Private Equity and Venture Capital Performance in Europe by Country	12
1.1.5	The Future of Private Equity and Venture Capital in Europe	13
1.2	Development of the Biotech Industry	14
1.2.1	Definition	14
1.2.2	Historical Background	16
1.2.3	Financing Biotech Start-ups	18
1.2.4	Exit Routes in the Biotech Industry	22
1.2.5	The Challenges to European Biotech	23
1.2.6	The Future of the European Biotech Industry	23
<b>2</b>	<b>Methodology</b>	27
2.1	Formulating the Research Goal	27
2.1.1	The Entrepreneur's Dilemma	27
2.1.2	The Investor's Dilemma	28
2.1.3	Financing Models	28
2.1.4	Interpersonal Relationships and Cooperations	30
2.1.5	Practical Guidelines for Entrepreneurs and Venture Capitalists	30
2.2	Conducting the Study	31

2.2.1	Qualitative Interviews	31
2.2.2	Selection of Interview Partners	31
2.3	Evaluating the Results	33
<b>3</b>	<b>Data Analysis and Interpretation of Results</b>	<b>35</b>
3.1	Description of Interview Partners	35
3.1.1	Entrepreneurs	35
3.1.2	Venture Capitalists	36
3.1.3	Other Investors	36
3.2	Major Characteristics of an Entrepreneur	36
3.2.1	The Dual Role of the Entrepreneur	37
3.3	Major Characteristics of a Venture Capitalist	38
3.3.1	Global Reach of the Fund	39
3.4	The Most Important Partnering Criteria	40
3.4.1	The Entrepreneur's Perspective	41
3.4.2	The Venture Capitalist's Perspective	41
3.4.3	The Perspective of Other Investors	42
3.5	Financing Models	42
3.5.1	Most Important Financing Models	43
3.5.2	New and Creative Financing Approaches	50
3.5.3	Differences Between Early- and Late-stage Financing	52
3.5.4	Differences Between Early- and Late-stage Valuation Techniques	53
3.6	Biotech Research Areas	58
3.6.1	Vaccines	59
3.6.2	Biotech Drug Development or Medical Technology and Devices?	60
3.7	Alliances and Funding in the Early Stage	61
3.7.1	Networking Between Venture Capitalists and Universities and Their Scientists	61
3.7.2	The Role of Government Grants	63
3.7.3	The Role of Business Angels	65
3.7.4	Preferred Deal Structure	67
3.7.5	Structuring the Board of Directors	68
3.8	Alliances and Funding in the Late Stage	70
3.8.1	Networking with Corporate Venture Capitalists	70
3.8.2	The Role of Banks as Capital Investors	73
3.8.3	The Importance of Milestone Payments	74
3.9	Exit Routes	74
3.9.1	Exit Preferences	74
3.9.2	The Role of New Markets	76
3.9.3	Prominent European IPO Success Stories	77
3.10	Primary Causes of Failure	78
3.10.1	The Entrepreneur's Perspective	78
3.10.2	The Venture Capitalist's Perspective	79
3.10.3	The Perspective of Other Investors	79
3.11	Best-practice Countries for Funding Biotech Start-ups	80

3.11.1	The Entrepreneur's Perspective	80
3.11.2	The Venture Capitalist's Perspective	81
3.11.3	The Perspective of Other Investors	81
3.12	Most Striking Differences between the US and European Venture Capital Markets	82
<b>4</b>	<b>Biotech Case Studies</b>	<b>87</b>
4.1	AUSTRIANOVA Biomanufacturing AG	87
4.2	AVIR Green Hills Biotechnology AG	90
4.3	EUCODIS GmbH	96
4.4	Intercell AG	103
4.5	onepharm Research & Development GmbH	111
<b>5</b>	<b>Summary and Conclusions</b>	<b>117</b>
5.1	The Challenge: When Science Meets Business	117
5.2	Checklists	118
5.2.1	Checklists for the Biotech Entrepreneur	118
5.2.2	Checklist for the Investor	124
5.3	Final Observations	127
<b>6</b>	<b>Outlook and Recommendations</b>	<b>131</b>
	<b>Epilogue</b>	<b>133</b>
	<b>References</b>	<b>137</b>
	<b>Appendix A: List of Abbreviations</b>	<b>141</b>
	<b>Appendix B: Glossary</b>	<b>145</b>
	<b>Appendix C</b>	<b>163</b>
C.1	Overview of Biotech Companies Mentioned in This Book	163
C.2	Overview of Venture Capital Companies Mentioned in This Book	165
	<b>Appendix D: Questionnaires</b>	<b>167</b>
D.1	Questionnaire for the Entrepreneur	167
D.2	Questionnaire for the Venture Capitalist	173
D.3	Questionnaire for the Group of Other Investors	180
	<b>Index</b>	<b>187</b>

